- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,034GBP
- Clinical Trials
- September 2021
- 60 Pages
Global
From €1441EUR$1,500USD£1,240GBP
- Report
- January 2022
- 200 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Drug Pipelines
- August 2020
- 50 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Clinical Trials
- August 2020
- 89 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Report
- May 2023
- 78 Pages
Global
From €3500EUR$3,904USD£3,119GBP
The Seborrhea Drug market is a subset of the Dermatological Drugs market, which includes medications used to treat skin conditions. Seborrhea Drugs are used to treat seborrheic dermatitis, a chronic skin condition characterized by red, scaly patches on the scalp, face, and other areas of the body. These drugs are typically topical medications, such as creams, ointments, and shampoos, and may contain active ingredients such as coal tar, salicylic acid, and corticosteroids.
Seborrhea Drugs are available both over-the-counter and by prescription, and are used to reduce inflammation, itching, and scaling associated with seborrheic dermatitis. In addition, these drugs may be used to treat other skin conditions, such as psoriasis and eczema.
Some companies in the Seborrhea Drug market include GlaxoSmithKline, Pfizer, Johnson & Johnson, Merck, and Novartis. Show Less Read more